{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:40:56Z","timestamp":1791337256774,"version":"4.3.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5499-2","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T13:03:02Z","timestamp":1554296582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6996-3572","authenticated-orcid":false,"given":"Jonathan","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Look Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Ghandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Czarnota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"issue":"15","key":"5499_CR1","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.29348","volume":"121","author":"SS Mougalian","year":"2015","unstructured":"Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544\u201352.","journal-title":"Cancer"},{"issue":"6","key":"5499_CR2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jamcollsurg.2015.02.011","volume":"220","author":"BK Killelea","year":"2015","unstructured":"Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220(6):1063\u20139.","journal-title":"J Am Coll Surg"},{"issue":"5","key":"5499_CR3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1245\/s10434-016-5733-y","volume":"24","author":"CA Puig","year":"2017","unstructured":"Puig CA, Hoskin TL, Day CN, Habermann EB, Boughey JC. National Trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast Cancer: a National Cancer Data Base Study. Ann Surg Oncol. 2017;24(5):1242\u201350.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"5499_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"P M","year":"2017","unstructured":"M P, M M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549\u201355.","journal-title":"JAMA Oncol"},{"issue":"4","key":"5499_CR5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","volume":"250","author":"KK Hunt","year":"2009","unstructured":"Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558\u201366.","journal-title":"Ann Surg"},{"issue":"Suppl 2","key":"5499_CR6","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","volume":"9","author":"CK Anders","year":"2009","unstructured":"Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9(Suppl 2):S73\u201381.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"5499_CR7","first-page":"106","volume":"12","author":"HA Wahba","year":"2015","unstructured":"Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106\u201316.","journal-title":"Cancer Biol Med"},{"issue":"5","key":"5499_CR8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778\u201385.","journal-title":"J Clin Oncol"},{"issue":"13","key":"5499_CR9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and bowel project protocol B-27. J Clin Oncol. 2006;24(13):2019\u201327.","journal-title":"J Clin Oncol"},{"issue":"22","key":"5499_CR10","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","volume":"19","author":"JA Hage van der","year":"2001","unstructured":"van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224\u201337.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5499_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2018","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339.","journal-title":"Lancet Oncol"},{"issue":"32","key":"5499_CR12","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","volume":"30","author":"EP Mamounas","year":"2012","unstructured":"Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5499_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ijrobp.2007.01.023","volume":"68","author":"SE McGuire","year":"2007","unstructured":"McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5499_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.clbc.2014.09.012","volume":"15","author":"H Nagar","year":"2015","unstructured":"Nagar H, Boothe D, Ginter PS, Sison C, Vahdat L, Shin S, et al. Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy. Clin Breast Cancer. 2015;15(2):128\u201334.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"5499_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5499_CR16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24(7):1037\u201344.","journal-title":"J Clin Oncol"},{"issue":"28","key":"5499_CR17","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414\u201322.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5499_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","volume":"16","author":"B Chevallier","year":"1993","unstructured":"Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16(3):223\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"5499_CR19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","volume":"12","author":"KN Ogston","year":"2003","unstructured":"Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320\u20137.","journal-title":"Breast"},{"issue":"2","key":"5499_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"5499_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/annonc\/mds493","volume":"24","author":"A Romero","year":"2013","unstructured":"Romero A, Garc\u00eda-S\u00e1enz JA, Fuentes-Ferrer M, L\u00f3pez Garcia-Asenjo JA, Furi\u00f3 V, Rom\u00e1n JM, et al. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol. 2013;24(3):655\u201361.","journal-title":"Ann Oncol"},{"key":"5499_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1186\/s12885-015-1664-4","volume":"15","author":"ML Marinovich","year":"2015","unstructured":"Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer. 2015;15:662.","journal-title":"BMC Cancer"},{"issue":"8","key":"5499_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.humpath.2007.11.019","volume":"39","author":"D Penault-Llorca","year":"2008","unstructured":"Penault-Llorca D, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurter M, et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008;39(8):1221\u20138.","journal-title":"Hum Pathol"},{"issue":"2","key":"5499_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejcsup.2013.07.028","volume":"11","author":"P Poortmans","year":"2013","unstructured":"Poortmans P. Optimal approach in early breast cancer: radiation therapy. EJC Suppl. 2013;11(2):27\u201336.","journal-title":"EJC Suppl"},{"issue":"8","key":"5499_CR25","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22(8):1736\u201347.","journal-title":"Ann Oncol"},{"issue":"2","key":"5499_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000351222","volume":"8","author":"HJ Senn","year":"2013","unstructured":"Senn HJ. St. Gallen consensus 2013: optimizing and personalizing primary curative therapy of breast cancer worldwide. Breast Care (Basel). 2013;8(2):101.","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"5499_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","volume":"31","author":"A Prat","year":"2013","unstructured":"Prat A, Cheang MC, Mart\u00edn M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013;31(2):203\u20139.","journal-title":"J Clin Oncol"},{"key":"5499_CR28","volume-title":"AJCC Cancer staging manual","author":"S Edge","year":"2010","unstructured":"Edge S, Byrd D, Comptom C, et al. AJCC Cancer staging manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"issue":"15","key":"5499_CR29","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Minckwitz von","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804.","journal-title":"J Clin Oncol"},{"key":"5499_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13014-016-0670-2","volume":"11","author":"R White","year":"2016","unstructured":"White R, Dinneen T, Makris A. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer. Radiat Oncol. 2016;11:93.","journal-title":"Radiat Oncol"},{"issue":"6","key":"5499_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","volume":"9","author":"M Cianfrocca","year":"2004","unstructured":"Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606\u201316.","journal-title":"Oncologist"},{"issue":"5","key":"5499_CR32","first-page":"732","volume":"237","author":"SW Beenken","year":"2003","unstructured":"Beenken SW, Urist MM, Zhang Y, Desmond R, Krontiras H, Medina H, Bland KI. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg. 2003;237(5):732\u20138.","journal-title":"Ann Surg"},{"issue":"9","key":"5499_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137885","volume":"10","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Park IA, Song IH, Kim SB, Jung KH, Ahn JH, et al. Comparison of pathologic response evaluation systems after anthracycline with\/without Taxane-based neoadjuvant chemotherapy among different subtypes of breast cancers. PLoS One. 2015;10(9):e0137885.","journal-title":"PLoS One"},{"issue":"1","key":"5499_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834015617459","volume":"8","author":"AU Kishan","year":"2016","unstructured":"Kishan AU, McCloskey SA. Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data. Ther Adv Med Oncol. 2016;8(1):85\u201397.","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"5499_CR35","first-page":"657","volume":"29","author":"CH Chapman","year":"2015","unstructured":"Chapman CH, Jagsi R. Postmastectomy radiotherapy after neoadjuvant chemotherapy: a review of the evidence. Oncology (Williston Park). 2015;29(9):657\u201366.","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"5499_CR36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.clon.2017.06.003","volume":"29","author":"H Cain","year":"2017","unstructured":"Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM. Neoadjuvant therapy in early breast Cancer: treatment considerations and common debates in practice. Clin Oncol (R Coll Radiol). 2017;29(10):642\u201352.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"23","key":"5499_CR37","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1200\/JCO.2004.11.129","volume":"22","author":"EH Huang","year":"2004","unstructured":"Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22(23):4691\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5499_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/JCO.2002.20.1.17","volume":"20","author":"TA Buchholz","year":"2002","unstructured":"Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002;20(1):17\u201323.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5499-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T04:32:44Z","timestamp":1663216364000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5499-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5499"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5499-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"15 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for this study was obtained through the Research Ethics Board of the Sunnybrook Health Sciences Centre. Informed written consent was obtained from participants according to REB guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"306"}}